Prostate Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Prostate cancer is the most common non-skin cancer in men and the second leading cause of cancer death in American men, with approximately 1.4 million new cases diagnosed globally per year and approximately 300,000 deaths annually. It arises from the glandular epithelium of the prostate, predominantly as acinar adenocarcinoma (the vast majority of cases). The disease exhibits extreme heterogeneity ranging from indolent Grade Group 1 tumors that may never cause symptoms in a lifetime, to highly aggressive de novo metastatic disease. African American men have the highest incidence (approximately 70% higher than white American men) and mortality from prostate cancer of any racial or ethnic group — a disparity driven by biological, genetic, and access-to-care factors. Most cases are diagnosed at localized stages through PSA screening, with the proportion presenting with de novo metastatic disease remaining at approximately 5-10% in countries with organized screening programs. Histological grading by the Gleason system (updated Grade Group 1-5) is the most important prognostic tool.

Advanced age is the single most important risk factor — prostate cancer is rare before age 40 and incidence rises sharply after 50. African American ethnicity confers approximately 70% higher incidence and twice the mortality compared to white Americans, reflecting both biological differences (higher tumor aggressiveness) and systemic healthcare disparities. A positive family history — particularly a father or brother with prostate cancer diagnosed before age 65 — approximately doubles an individual's lifetime risk. Germline BRCA2 mutations confer a 3-8 fold elevated lifetime risk of prostate cancer and are associated with more aggressive disease — the actionable implications include increased surveillance and eligibility for PARP inhibitor therapy. BRCA1, ATM, PALB2, CDK12, and Lynch syndrome (mismatch repair) genes are additional hereditary risk-conferring variants. A high-fat, high-dairy Western diet and obesity have been associated with increased risk in epidemiological studies. Testosterone exposure is a necessary permissive factor for prostate cancer growth, but exogenous testosterone replacement therapy has not been proven to cause de novo prostate cancer.

Early-stage prostate cancer confined to the gland is typically entirely asymptomatic, which is the fundamental reason PSA screening programs were developed. The prostate is anatomically positioned such that early tumors do not obstruct urinary flow. When lower urinary tract symptoms (LUTS) develop — urinary frequency, urgency, nocturia, weak or interrupted urinary stream, hesitancy, or incomplete bladder emptying — they usually reflect benign prostatic hyperplasia (BPH) rather than prostate cancer, since BPH affects the central transition zone while prostate cancer predominantly arises from the peripheral zone. Hematospermia (blood in semen) may occur. As disease progresses locally, urinary obstruction and erectile dysfunction can result from local invasion. Metastatic prostate cancer — most commonly to the axial skeleton (spine, pelvis, ribs, femora) — produces severe bone pain, pathological fractures, spinal cord compression (causing paraparesis or paralysis), and weight loss. Anemia, fatigue, and lymphedema from pelvic node involvement occur in advanced metastatic disease.

PSA testing followed by multiparametric MRI (mpMRI) with PI-RADS scoring (1-5) for lesion characterization is the current state-of-the-art pre-biopsy evaluation. PI-RADS 4 and 5 lesions undergo targeted MRI-guided biopsy combined with systematic 12-core transrectal or transperineal biopsy. Gleason grading of biopsy cores and the Grade Group system (1-5, corresponding to Gleason scores 6, 7a, 7b, 8, 9-10) is fundamental to risk stratification. TNM clinical staging determines localization versus regional versus distant spread. Germline testing for BRCA1/2, ATM, CDK12, PALB2, and Lynch syndrome genes is recommended for all men with high-risk, very-high-risk, locally advanced, or metastatic prostate cancer. Genomic classifiers (Decipher, Prolaris, Oncotype DX GPS) predict metastatic risk in intermediate-risk localized disease. PSMA PET/CT (68Ga-PSMA or 18F-DCFPyL) has largely replaced conventional bone scan and CT for staging due to superior sensitivity for nodal and bony metastasis.

Active surveillance with scheduled PSA, MRI, and repeat biopsy is the standard of care for Grade Group 1 (very low and low risk) and selected Grade Group 2 (favorable intermediate risk) prostate cancer. Radical prostatectomy (robotic-assisted laparoscopic prostatectomy, RALP, or open retropubic) offers equivalent oncological outcomes to radiotherapy for localized disease, with different side effect profiles. External beam radiotherapy (EBRT) using IMRT or SBRT (stereotactic body radiotherapy), often combined with brachytherapy boost and short-course ADT for intermediate-risk disease, is a well-established organ-preserving alternative. For locally advanced disease (T3-T4 or high-grade), ADT combined with long-course EBRT (with or without abiraterone, enzalutamide, or darolutamide based on STAMPEDE/ARCHES/ENZAMET trials) is standard. Metastatic hormone-sensitive prostate cancer (mHSPC): ADT doublet or triplet — ADT plus docetaxel (CHAARTED), or ADT plus abiraterone (LATITUDE), or ADT plus enzalutamide, or triplet ADT + abiraterone + docetaxel (PEACE-1). Metastatic castration-resistant prostate cancer (mCRPC): abiraterone, enzalutamide, or darolutamide; cabazitaxel; PARP inhibitors (olaparib for BRCA1/2, rucaparib for BRCA2); and 177Lu-PSMA-617 (VISION trial) for PSMA-positive disease.

5-alpha reductase inhibitors (finasteride, dutasteride) reduce prostate cancer incidence in large randomized trials (PCPT, REDUCE), but have not been widely adopted for prevention due to concerns about a possible increase in high-grade cancer detection, now generally considered an artifact of improved tumor sampling in smaller glands. Maintaining a healthy weight, engaging in regular physical activity, and following a diet rich in vegetables and low in processed red meat may provide modest risk reduction based on epidemiological evidence. Lycopene (from tomatoes), green tea, and vitamin E have been investigated but not proven beneficial in clinical trials. PSA screening starting at age 40-45 for high-risk men (African American, germline BRCA2 carriers, strong family history) and shared decision-making at ages 50-69 for average-risk men allows detection at potentially curable stages. Annual PSA monitoring is standard for all men with BRCA2 germline mutations from age 40. Germline testing is recommended for all patients with high-risk, very-high-risk, regional, and metastatic prostate cancer.

Men aged 50-69 without risk factors should discuss PSA screening with their primary care physician, weighing the benefits of early detection against the risks of overdiagnosis and overtreatment. Men at higher risk — African American men and those with a father, brother, or son diagnosed with prostate cancer — should initiate this conversation at age 40-45. Any man who develops bone pain — particularly in the back, hips, or ribs — that is constant, does not improve with rest, or is present at night should seek evaluation promptly. Unexplained urinary difficulty, especially if a patient has a known elevated PSA, should be assessed by a urologist. Sudden-onset back pain with any lower extremity weakness, numbness, or loss of bladder or bowel control in a man with prostate cancer is a potential oncological emergency (spinal cord compression) requiring same-day MRI and urgent oncology or spine surgery assessment.

Localized prostate cancer: 5-year survival approximately 98-100%. Regional disease: nearly 100%. Distant metastasis (mHSPC): approximately 30-35% 5-year survival, significantly improving with modern ADT-based doublets and triplets. mCRPC: median OS has improved to approximately 3-4 years with sequential novel hormonal agents and 177Lu-PSMA. Most prostate cancer deaths occur 10 or more years after diagnosis. The prognosis for Prostate Cancer: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.